Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

BackgroundThe administration of second- or third-generation anti-CD19 chimeric antigen receptor (CAR) T cells has remarkably improved the survival of patients with relapsed or refractory B cell malignancies. However, there are limited clinical results from fourth-generation CAR-T cell therapy, and t...

Full description

Bibliographic Details
Main Authors: Xuan Zhou, Sanfang Tu, Chunsheng Wang, Rui Huang, Lan Deng, Chaoyang Song, Chunyan Yue, Yanjie He, Jilong Yang, Zhao Liang, Anqin Wu, Meifang Li, Weijun Zhou, Jingwen Du, Zhenling Guo, Yongqian Li, Cheng Jiao, Yuchen Liu, Lung-Ji Chang, Yuhua Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
CD19
chimeric antigen receptor T cells
non-Hodgkin’s lymphomas
cytokine release syndrome
B cell lymphoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.564099/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.564099/full

Similar Items